Clustering Insights is the podcast series that engages with key players who are active in the life sciences sector. This series will provide opinion and thought leadership from investors, developers, funders, occupiers, technical consultants and many more to give you an inside view of the sector and the role that the built environment can play to support its continued growth.
Addressing the issues of supply and demand in life sciences - with Neelam Patel, Chief Executive Officer at MedCity
In our latest podcast, Chris Walters, JLL’s Head of UK Life Sciences, is joined by Neelam Patel, CEO of MedCity, the life sciences cluster organisation for London, which plays a pivotal role in bridging industry, NHS and academia to boost innovation and economic growth. In the podcast they discuss the challenges facing the life sciences industry from the point of view of the supply and demand of real estate – and explore some of the solutions MedCity are currently working on to help solve the problem, both in London and beyond.
Dr Glenn Crocker – Senior Consultant - Life Sciences, JLL
Dr Glenn Crocker and his team advise landowners, investors and developers on where and how to buy, sell, develop, finance and attract occupiers to life science real estate. The team also supports occupiers to be in the optimum location with the right, most efficiently run property portfolio to deliver their growth strategy.
Glenn is also Chairman and Chief Investment Officer of BioCity Group, which provides facilities and develops ecosystems to support life science companies, including providing equity investment. He was the founding CEO of the business until the end of 2018. He has a DPhil in Immunology from Oxford University and qualified as a chartered accountant with EY, focusing on working with biotech companies in Palo Alto, California and Cambridge, UK, where he headed up the UK Biotech practice for EY.
He is a non-executive director of a number of life science companies and consults on business incubation, start-up creation and cluster growth. He has been directly involved in investing in life science companies through BioCity’s own or managed funds since 2006.
In 2014 Glenn received an MBE for services to the biotechnology industry.
Rachel Dickie - Director of Urban Regeneration, Legal & General Capital.
Rachel is an Investment Director in Legal & General’s Future Cites business, leading the Urban Regeneration team. She is responsible for the sourcing, structuring and investment management of real estate projects and partnerships, including Cardiff Central Square, Newcastle Helix, Bath Quays North, L&G’s investment in Bruntwood SciTech and the recent joint venture with Oxford University. In November 2019, Rachel was appointed as the Interim CEO of the Oxford University JV.
She joined Legal & General in 2016 from Tishman Speyer, a US private equity real estate investor, developer and fund manager where she carried out several roles across real estate asset management, fund management and business development.
Rachel holds an MA in economics from the University of Cambridge.
Chris Walters - Head of UK Life Sciences, JLL
Chris leads the Life Science business at JLL that focuses on the science, technology and innovation sector. Through experience working with NHS Trusts; academic and research institutions; local authorities; and a diverse set of private sector clients covering private equity, institutional capital and sovereign wealth; Chris is recognised as an industry-leading expert on both the UK and European markets.
Chris’s responsibilities are focused on providing strategic recommendations on a range of development and investment opportunities comprising development consultancy, appraisals and transactional advice. In addition, he works closely with all aspects of the occupier business to find tailored solutions to their needs across the full spectrum of the science and technology industry.
Douglass Cuff is the Vice President of UK Real Estate for IQHQ, Inc.
Douglass has over 20 years’ experience working in life sciences real estate sector. Prior to IQHQ, He had various roles at BioMed Realty during his 14-year tenure.
Initially, he was responsible for overseeing the entire 1 million sq ft life science real estate portfolio in Cambridge, MA. Eventually, Douglass moved onto overseeing the completion and operation of ‘The Center for Life Science | Boston’; which is an 18 storey, first-class research facility which houses the various research groups of Children’s Hospital Boston, Beth Israel Deaconess Medical Center and the Dana Farber Cancer Institute.
Douglass then relocated to Cambridge, UK in 2012 with the acquisition of Granta Park. He expanded the initial UK portfolio by negotiating 2 pre-lets at Granta Park as well as closing a partnership with the Biotechnology and Biological Sciences Research Council at the Babraham Research Campus. Doug received a Master’s in Business Administration from Boston University and a Bachelor of Science in Biological Sciences from Fordham University in New York City.
Matthew Jones - Partner, Hoare Lea
Matt is a Partner of Hoare Lea and has played a principal role in the strategic development of Hoare Lea’s work in the science & research sector. He has acted as managing partner on a host of key science & research projects in Oxford, Cambridge and London. He was one of the co-founders of both Hoare Lea’s Oxford and Cambridge offices, and is currently leading on further expansion for the firm.
Pete Wilder, Head of Property at Oxford Sciences Innovation (OSI)
Pete joined OSI as the Head of Property in July 2019. Prior to this, he was a Partner at Bidwells, a property consultancy with a focus on the science and technology sector. Pete was previously a Director at JLL, where he advised Deutsche Bank, GSK and Sony. He also worked with corporate clients for BNP Paribas Real Estate. Pete holds a BA in French and Italian from Bristol University and is a Member of the Royal Institution of Chartered Surveyors. At OSI, Pete is responsible for managing the growing property portfolio and for providing strategic advice to portfolio companies.
Travis McCready - Executive Managing Director/National Practice Leader, US Life Sciences Markets, JLL
Travis McCready is the National Practice Leader for JLL’s US life sciences real estate markets practice, which includes brokerage, capital markets, advisory and analytics, project and development services, and valuation for life sciences occupiers, developers and investors. He has over 25 years of experience leading public, private, and nonprofit ventures with a focus on technology and innovation based economic development. The former President & CEO of the $1.6 billion life sciences funding agency Massachusetts Life Sciences Center, he remains active in the life sciences community serving as director and scientific advisor to start-ups and initiatives focused on rare disease diagnostics, the microbiome, and advanced biomanufacturing.
Travis is the co-chair of the Academic Institute Advisory Board at Atrius Health, the largest independent physician-led healthcare organization in the Northeast. He is passionate about supporting tech-based entrepreneurship and serves on the boards of business accelerators MassChallenge and Lever, and wet lab incubator MBI. He also serves on the boards of public media giant WGBH, and the world-renowned Institute of Contemporary Art, Boston. No stranger to public service, Travis has served on the Economic Development Planning Council under three Massachusetts governors and has been appointed to state and national initiatives ranging from the arts to advanced manufacturing.
A native of New York City, Travis received his B.A. from Yale University, and J.D. from the University of Iowa.
Stuart Grant - Chief Executive Officer, Harwell Science & Innovation Campus and Co-Founder, CoreLife Investors
Stuart is Co-Founder of CoreLife Investors, adviser to Brookfield’s Real Estate Group, CEO of Harwell Campus and has more than 25 years of real estate experience.
Stuart began his career in Asia-Pacific as an International Executive with Jardine Matheson Ltd. before starting his real estate investment career at Blackstone in London and Hong Kong. During his 18 years at Blackstone, he held a variety of leadership positions including Senior Managing Director and Head of Asset Management for the Asia-Pacific region. He played a key role in building Blackstone’s Real Estate business in the region including overseeing more than $20 billion of investments in Greater China, India, Singapore, Japan, Korea and Australia. He also served on the firm’s Global Real Estate Investment Committee.
Stuart returned to the UK in 2018 as Managing Director of Stanhope Plc to help grow one of London’s leading developers. He is also a member of the Investment Committee and Advisory Board of Mitheridge Capital and sits on Harwell’s HealthTec, Space and EnergyTec boards. Stuart has supported other organisations and boards including the Urban Land Institute Dumfries House, Great Ormond Street Hospital and Maggie’s Cancer Care Centres.
Stuart graduated from the University of St. Andrews and completed a Masters in Real Estate Investment and Finance at New York University.
Dr Barbara Ghinelli – Director, Harwell Campus Business Development and Clusters at Science and Technology Facilities Council
Barbara co-created the cluster model at the Harwell and Daresbury Science & Innovation Campuses and oversees their development. She has established a high profile for the Space, HealthTec and EnergyTec Clusters and is leading the development of a new Digital Cluster.
Barbara joined STFC in 2010 as Executive Director of Business Development. Successes included the creation of International Space Innovation Centre (now Satellite Application Catapult) at Harwell and of the High Performance Computing Centre (Hartree) at Daresbury.
Barbara joined STFC from EADS Astrium (now Airbus DS), where she managed Business Development across Europe for the €3.2 billion joint ESA / EU Earth Observation Programme for Global Monitoring of Environment and Security (now Copernicus) and secured a number of large contracts. She graduated in Electronic Engineering at the University of York, completed her PhD in Artificial Intelligence and Radar Imaging at the University of Sheffield and holds a Certificate in Management from the Open University.
Amrit Chaudhuri – Co-Founder and Chief Executive Officer at SmartLabs
Amrit is a recognised leader and entrepreneur in life sciences who has been involved in many FDA clinical trials, holds numerous patents, and successfully created five companies including Advanced Peptides, a specialty contract research organisation focused on peptide chemistry.
In 2017, INC Magazine named him one of the "Top 20 Healthcare Innovators and Entrepreneurs".
Amrit co-founded SmartLabs in 2015, which designs, builds, and operates integrated, enterprise-grade research environments, including multifunctional research and development labs, vivaria, process development, pilot-scale manufacturing, and cGMP suites for companies of all sizes.
Charles Walford - Senior Development Director and Head of Life Sciences at Stanhope
Charles is a Director at Stanhope. Since joining in 1989, he has developed a specialism in the ‘front end’ of the development process including identification and securing new opportunities, managing all aspects of pre-development including planning as well as general de-risking projects to enable implementation to take place. Charles has been involved with some major mixed use projects including Ruskin Square, Television Centre and the Royal Albert Dock. Currently, Charles is heading up the British Library project in its early stages, as a result he has developed a specific interest and expertise in the Life Science sector. He is a Chartered Surveyor, has looked after PR and communications for Stanhope and was an advisor to the Photographers' Gallery.
Neelam Patel, Chief Executive Officer, MedCity
Neelam is CEO of MedCity, the life sciences cluster organisation for London, which plays a pivotal role in bridging industry, NHS and academia to boost innovation and economic growth. Neelam’s extensive experience spans the private, public and not-for-profit sectors. She has worked with the Association of British Pharmaceutical Industries, the European Innovative Medicines Initiative and collaborated with NHS England, NICE and Public Health England.
Neelam regularly supports companies with R&D, advising on the UK regulatory and access landscape, and is actively working to shape delivery of appropriate real estate infrastructure for life sciences companies. Other roles include seats on the Mayor of London’s Workspace Advisory Group; the advisory board of the Innovation Centre in Digital Molecular Technologies at the University of Cambridge, London Health Data Strategy Programme Stakeholder Board, and the board of the Health Research Authority.
Enjoying our podcast? Subscribe now
Jones Lang LaSalle (JLL), together with its subsidiaries and affiliates, is a leading global provider of real estate and investment management services. We take our responsibility to protect the personal information provided to us seriously.
Generally the personal information we collect from you are for the purposes of dealing with your enquiry.
We endeavor to keep your personal information secure with appropriate level of security and keep for as long as we need it for legitimate business or legal reasons. We will then delete it safely and securely. For more information about how JLL processes your personal data, please view our privacy statement.